Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
teneligliptin + pioglitazone
- Development stage
- Unknown
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Teneligliptin + pioglitazone is a fixed-dose combination of two oral antidiabetic agents used for the treatment of type 2 diabetes mellitus in adults. Teneligliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that increases incretin levels, thereby stimulating insulin secretion and decreasing glucagon release from the pancreas, which helps lower blood glucose. Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator–activated receptor gamma (PPARγ), increasing insulin sensitivity in peripheral tissues and improving glucose uptake. The combination provides synergistic glycemic control by targeting both insulin secretion and sensitivity, making it effective for patients inadequately controlled on monotherapy or lifestyle interventions[1][4][5][6].
- Brand names
- Zita-PioZita Plus-PioTencrine PTendia-PTenepride PJoten P
- Other names
- pioglitazone + teneligliptin
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on teneligliptin + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on teneligliptin + pioglitazone.